Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults

NCT02691130 is registered in ClinicalTrials.gov with BiondVax Pharmaceuticals ltd. as lead sponsor.

NCT NCT02691130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02691130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults
Lead sponsor
BiondVax Pharmaceuticals ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
January 31, 2017
Enrollment
224 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, influenza